EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.37m) in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (‘DTIF’).
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.